CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 38 enrolled
Drug / intervention
CGRP antibodydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06018025
NCT06018025N/ACompleted
CompareCT.gov

New Daily Persistent Headache (NDPH): Biomarker Study and Therapy in Children and Adolescents

Duke University·observational·Posted Aug 30, 2023·Updated Dec 1, 2025

In Brief

An observational study evaluating CGRP antibody for New Persistent Daily Headache. Completed, enrolled 38 participants across 1 site.

Detailed Summary

This study will recruit pediatric patients with NDPH (New Daily Persistent Headache), characterize their headache in a standard manner, and treat the NDPH with standard medications used for treatment of headaches in this population. Response to treatment with CGRP blocking Ab medications will be evaluated. Biomarkers related to headache disorders will be measured before and after treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNew Persistent Daily Headache
CountriesUnited States
CollaboratorsInternational Headache Society

Timeline

N/ACompletedFinished
202420252026
First PostedAug 30, 2023
Enrollment StartApr 15, 2024
Primary CompletionMay 29, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.8 years ago

Interventions

CGRP antibodydrug

treatment with CGRP antibody for 4 months